FindTrial
Sign In

Ivermectin as a possible treatment for COVID-19

Ivermectin as a potential treatment for COVID 19: A double blind randomized placebo-controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/08/027225
Enrollment
90
Registered
2020-08-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Ivermectin: 12 mg orally to be administered once daily on days 1 and 2 Control Intervention1: Placebo tablets: A placebo tablet similar to Ivermectin 12 mg (provided by the manufacturer

Sponsors

AIIMS Patna
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients admitted with COVID-19 with mild to moderate severity

Exclusion criteria

Exclusion criteria: History of allergy to Ivermectin Unwillingness to participate in the study

Design outcomes

Primary

MeasureTime frame
Negative RT-PCRTimepoint: Day 6—

Secondary

MeasureTime frame
Discharge by day 10Timepoint: Day 10;ICU AdmissionTimepoint: NA;In-hospital mortalityTimepoint: NA;Mechanical VentilationTimepoint: NA—

Countries

India

Contacts

Public ContactRavi Kirti

All India Institute of Medical Sciences

drravikirti@aiimspatna.org9572424447

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026